Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Managing recurrent Clostridium difficile infection (CDI) presents a significant challenge for clinicians and patients. Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent CDI, yet availability of a standardized, safe, and effective product has been lacking. Our aim in this study was to assess the safety and effectiveness of RBX2660 (microbiota suspension), a commercially prepared FMT drug manufactured using standardized processes and available in a ready-to-use format. METHODS: Patients with at least 2 recurrent CDI episodes or at least 2 severe episodes resulting in hospitalization were enrolled in a prospective, multicenter open-label study of RBX2660 administered via enema. Intensive surveillance for adverse events (AEs) was conducted daily for 7 days following treatment and then at 30 days, 60 days, 3 months, and 6 months. The primary objective was product-related AEs. A secondary objective was CDI-associated diarrhea resolution at 8 weeks. RESULTS: Of the 40 patients enrolled at 11 centers in the United States between 15 August 2013 and 16 December 2013, 34 received at least 1 dose of RBX2660 and 31 completed 6-month follow-up. Overall efficacy was 87.1% (16 with 1 dose and 11 with 2 doses). Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most common. The frequency and severity of AEs decreased over time. Twenty serious AEs were reported in 7 patients; none were related to RBX2660 or its administration. CONCLUSIONS: Among patients with recurrent or severe CDI, administration of RBX2660 via enema appears to be safe and effective. CLINICAL TRIALS REGISTRATION: NCT01925417.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [64]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 2×
“Two randomized controlled trials of FMT predominantly recorded mild AEs similar to those found in our study [11, 27].”
BackgroundResultCohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · cited 1×
“Clostridium difficile infection (CDI) has become one of the most common healthcare-associated infections in the United States, affecting more than 500 000 people annually [1].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003 · cited 2×
“Minor and self-limited gastrointestinal symptoms similar to those seen in this study appear to be common [17].”
BackgroundResultKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Most studies that have assessed the impact of FMT are retrospective case series or systematic reviews of heterogeneously screened sources of microbiota with limited safety data [6, 7, 10].”
BackgroundBreaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“Three systematic reviews and case series that included more than 5 patients and use of nonstandardized FMT products and procedures [3, 4, 7, 18] have concluded that AEs are infrequent.”
BackgroundKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636 · cited 1×
“One patient died during sedation for a colonoscopy [26].”
BackgroundSelf-citationYoungster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629 · cited 1×
“In a second study that used an encapsulated product, 30% of patients experienced cramps and bloating, which resolved within 3 days [13].”
Background
Cited by
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Sorbara, M. T., & Pamer, E. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00667-9 · Cited by 468
Clinical Application and Potential of Fecal Microbiota Transplantation
Ooijevaar, R. E., Terveer, E. M., Verspaget, H. W., Kuijper, E. J., & Keller, J. J. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-111717-122956 · Cited by 336
“FMT can be delivered through the upper GI route, via a duodenal tube or capsules taken orally (31, 32), or through the lower GI route, via colonoscopy or enema (30, 35).”
BackgroundMullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Understanding the impact of antibiotic perturbation on the human microbiome
Schwartz, D. J., Langdon, A. E., & Dantas, G. (2020) · Genome Medicine · doi:10.1186/s13073-020-00782-x · Cited by 322
“and steroid non-responsive colitis [103, 105, 107].”
Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., Lombardo, M.-J., Vulic, M., Ohsumi, T., Winkler, J., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv766 · Cited by 321
Self-citationKhanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., et al. (2022) · Drugs · doi:10.1007/s40265-022-01797-x · Cited by 301
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 300
“%) for repeat FMT based on 24 studies with 1855 patients and 84% (95% CI 80 (cid:1) 88%, I 2 =86”
Antibiotics in the clinical pipeline as of December 2022
Butler, M. S., Henderson, I. R., Capon, R. J., & Blaskovich, M. A. T. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-023-00629-8 · Cited by 239
“RBX2660 is a liquid suspension donor fecal microbiota that has been screened for bacterial, viral and parasitic pathogens [60, 61] that was developed by Rebiotix Inc (Roseville, MN, USA), which is part of Ferring Pharmaceuticals (Saint-Prex, Switzerland).”
Staley, C., Hamilton, M. J., Vaughn, B. P., Graiziger, C. T., Newman, K. M., Kabage, A. J., Sadowsky, M. J., & Khoruts, A. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.6 · Cited by 244
Non-traditional Antibacterial Therapeutic Options and Challenges
Theuretzbacher, U., & Piddock, L. J. V. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.06.004 · Cited by 230
El Hage, R., Hernandez-Sanabria, E., & Van de Wiele, T. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01889 · Cited by 185
“These therapeutic approaches are intended to treat CDI, and that can be used as an alternative for FMT. Synthetic microbial communities designed for transplants are expected to meet production, mode of action and safety standards (Orenstein et al., 2015; van der Lelie et al., 2017).”
BackgroundTariq, R., Pardi, D. S., Bartlett, M. G., & Khanna, S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy721 · Cited by 175
Self-citationKhanna, S., Vazquez-Baeza, Y., González, A., Weiss, S., Schmidt, B., Muñiz-Pedrogo, D. A., Rainey, J. F., Kammer, P., Nelson, H., Sadowsky, M., et al. (2017) · Microbiome · doi:10.1186/s40168-017-0269-3 · Cited by 164
Self-citationSartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0228-3 · Cited by 159
Bella, S. D., Sanson, G., Monticelli, J., Zerbato, V., Principe, L., Giuffrè, M., Pipitone, G., & Luzzati, R. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00135-23 · Cited by 230
Probiotics for prevention of Clostridium difficile infection
Mills, J. P., Rao, K., & Young, V. B. (2018) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000410 · Cited by 161
Update of treatment algorithms for Clostridium difficile infection
Ooijevaar, R. E., van Beurden, Y. H., Terveer, E. M., Goorhuis, A., Bauer, M. P., Keller, J. J., Mulder, C. J. J., & Kuijper, E. J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.022 · Cited by 150
“[69] 40 Enema No 8 weeks 7 days vancomycin 125 mg four times a day 50 g faeces diluted to 150 mL 1st FMT: 52% 2nd FMT: 87% Hota et al.”
MethodDubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy259 · Cited by 140
Self-citationSun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 127
Ramai, D., Zakhia, K., Fields, P. J., Ofosu, A., Patel, G., Shahnazarian, V., Lai, J., Dhaliwal, A., Reddy, M., & Chang, S. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06185-7 · Cited by 113
Xu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949490 · Cited by 127
Advances in the diagnosis and treatment of Clostridium difficile infections
Peng, Z., Ling, L., Stratton, C. W., Li, C., Polage, C. R., Wu, B., & Tang, Y. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-017-0019-4 · Cited by 121
Ramai, D. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0328 · Cited by 93
“Orenstein et al 2016 [31] 31 Enema 50 Not reported 87.”
BackgroundLangdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C. D., Dubberke, E. R., & Dantas, G. A. (2021) · Genome Medicine · doi:10.1186/s13073-021-00843-9 · Cited by 93
Self-citationNicco, C., Paule, A., Konturek, P. C., & Edeas, M. A. (2020) · Diseases · doi:10.3390/diseases8020009 · Cited by 98
Therapies to modulate gut microbiota: Past, present and future
Gupta, A., Saha, S., & Khanna, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i8.777 · Cited by 94
Orenstein, R., Dubberke, E. R., Khanna, S., Lee, C., Yoho, D. S., Johnson, S., Hecht, G. A., DuPont, H. L., Gerding, D. N., Blount, K., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07256-y · Cited by 90
“RBX2660 doses were manufactured from human stool as previously described [6] and in accordance with proprietary process and quality controls agreed upon with the FDA within the IND application and in Clinical Trials Registration NCT02589847 (10/28/2015)”
BackgroundMethodResultInfluentialSelf-citationFecal Microbiota Transplantation in Inflammatory Bowel Disease
Boicean, A., Bîrluțiu, V., Ichim, C., Anderco, P., & Bîrsan, S. (2023) · Biomedicines · doi:10.3390/biomedicines11041016 · Cited by 94
“By performing FMT via a colonoscopy, the colon is recolonized with beneficial bacteria and cleansed, which reduces the number of residual organisms and spores in the colon [36,48,49].”
MethodMullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.07.037 · Cited by 79
The microbiome and host mucosal interactions in urinary tract diseases
Jones, B., Chonwerawong, M., Marcelino, V. R., Deshpande, A., Forster, S. C., & Starkey, M. R. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00372-5 · Cited by 91
Dubberke, E. R., Mullane, K. M., Gerding, D. N., Lee, C. H., Louie, T. J., Guthertz, H., & Jones, C. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw133 · Cited by 75
Self-citationLee, C., Louie, T., Bancke, L. L., Guthmueller, B., Harvey, A., Feuerstadt, P., Khanna, S., Orenstein, R., & Dubberke, E. R. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231174277 · Cited by 82
Self-citationA Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea
Abad, C. L. R., & Safdar, N. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.02.010 · Cited by 91
Clinical translation of microbe‐based therapies: Current clinical landscape and preclinical outlook
Vargason, A. M., & Anselmo, A. C. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10093 · Cited by 71
Fecal Microbiota Transplantation
Cheng, Y., & Fischer, M. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1760865 · Cited by 76
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2223345 · Cited by 71
Blount, K. F., Shannon, W. D., Deych, E., & Jones, C. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz095 · Cited by 66
Drewes, J. L., Corona, A., Sanchez, U., Fan, Y., Hourigan, S. K., Weidner, M., Sidhu, S. D., Simner, P. J., Wang, H., Timp, W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130848 · Cited by 64
Status of vaccine research and development for Clostridium difficile
Riley, T. V., Lyras, D., & Douce, G. R. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.052 · Cited by 69
Kwak, S., Choi, J., Hink, T., Reske, K. A., Blount, K., Jones, C. R., Bost, M. H., Sun, X., Burnham, C. D., Dubberke, E. R., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00907-9 · Cited by 66
Self-citationMicrobiota Replacement Therapies: Innovation in Gastrointestinal Care
Khanna, S. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.923 · Cited by 62
Dieterle, M. G., Rao, K. K., & Young, V. B. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13958 · Cited by 71
Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis
Rapoport, E. A., Baig, M., & Puli, S. R. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0695 · Cited by 89
“078 Orenstein et al 2015 [32] 31 46 0 0 6.”
BackgroundKhanna, S., Pardi, D. S., Jones, C. R., Shannon, W. D., Gonzalez, C., & Blount, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1430 · Cited by 60
Self-citationZhang, J., Zhu, G., Wan, L., Liang, Y., Liu, X., Yan, H., Zhang, B., & Yang, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123658 · Cited by 53
Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
Vasilescu, I.-M., Chifiriuc, M. C., Pîrcălăbioru, G. G., Filip, R., Bolocan, A., Lazăr, V., Diţu, L.-M., & Bleoţu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651081 · Cited by 61
Dubberke, E. R., Orenstein, R., Khanna, S., Guthmueller, B., & Lee, C. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00744-3 · Cited by 57
Self-citationRidinilazole: a novel therapy for Clostridium difficile infection
Vickers, R. J., Tillotson, G., Goldstein, E. J. C., Citron, D. M., Garey, K. W., & Wilcox, M. H. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.026 · Cited by 54
“In addition to FMT, the oral microbiome therapeutics SER-109 and RBX2660 appear to be promising bacteriotherapies for CDI [55,56].”
BackgroundStripling, J., & Rodriguez, M. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.08.010 · Cited by 48
Update on Treatment of Clostridioides difficile Infection
Cho, J. M., Pardi, D. S., & Khanna, S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.006 · Cited by 53
Self-citationTherapeutic manipulation of the microbiota: past, present, and considerations for the future
Young, V. B. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.001 · Cited by 54
“A number of investigators are trying to process fecal material to obtain a more refined therapeutic product [34].”
BackgroundNew and emerging therapies for Clostridium difficile infection
Martin, J. S. H., & Wilcox, M. H. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000320 · Cited by 50
“In the first of two phase 2 studies, 34 subjects (with >2 recurrent CDI episodes or >2 severe episodes resulting in hospitalization) received at >1 dose of RBX2660 and 31 completed 6 months follow up.(61) Following a 10-14 day course of CDI antibiotics and a 24-48 hour washout period, RBX2660 was administered as a sin…”
BackgroundDiet and Microbiome-Directed Therapy 2.0 for IBD
Ananthakrishnan, A. N., Whelan, K., Allegretti, J. R., & Sokol, H. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.049 · Cited by 52
Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections
Lewis, B. B., & Pamer, E. G. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093549 · Cited by 50
Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No’
Tan, X., & Johnson, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102092 · Cited by 49
Caenepeel, C., Deleu, S., Vázquez-Castellanos, J. F., Arnauts, K., Braekeleire, S., Machiels, K., Baert, F., Mana, F., Pouillon, L., Hindryckx, P., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.017 · Cited by 51
Porcari, S., Fusco, W. G., Spivak, I., Fiorani, M., Gasbarrini, A., Elinav, E., Cammarota, G., & Ianiro, G. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00357-6 · Cited by 47
Fasano, A., Chassaing, B., Haller, D., Ventura, E. F., Collado, M. C., Pastor, N., Koren, O., & Canani, R. B. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2392009 · Cited by 49
“…syndrome after intervention when compared to dietary interventions that do consider FMTs. 88,89 In this line, Food and Drug Administration (FDA) approvals of FMT therapies for recurrent C. difficile infections include the RBX2660 (live biotherapeutic), 90 and the Ser 109 (synthetic biotherapeutic).”
BackgroundThiemann, S., Smit, N., & Strowig, T. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_504 · Cited by 47
“In the meantime several companies already have started clinical trials with “semi-standardized” donor material to treat recurrent CDI including a successful phase II trial by Rebiotix (Orenstein et al. 2016).”
BackgroundFecal microbiota transplantation: History, procedure and regulatory considerations
Thanush, D., & Venkatesh, M. P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104204 · Cited by 44
Feuerstadt, P., Chopra, T., Knapple, W., Hise, N. W. V., Dubberke, E. R., Baggott, B. B., Guthmueller, B., Bancke, L. L., Gamborg, M., Steiner, T. S., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae437 · Cited by 40
“Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated infections in the United States (US) [1], with a significant clinical and socioeconomic burden [2, 3].”
Self-citationControl of Clostridium difficile Infection by Defined Microbial Communities
Collins, J., & Auchtung, J. M. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0009-2016 · Cited by 44
Translating Microbiome Research From and To the Clinic
Zhang, Z. J., Lehmann, C. J., Cole, C. G., & Pamer, E. G. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-022206 · Cited by 33
Emerging Options for the Prevention and Management of Clostridioides difficile Infection
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Drugs · doi:10.1007/s40265-022-01832-x · Cited by 36
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad642 · Cited by 39
Adverse events of fecal microbiota transplantation: a metaanalysis of high-quality studies
Michailidis, L., Currier, A. C., Le, M., & Flomenhoft, D. R. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0655 · Cited by 48
“We performed an additional analysis that included all 60 studies of the preliminary selection [7-9,14-17,22,23,50-54,59-104].”
MethodFecal microbiota transplantation: present and future
Cha, R. R., & Sonu, I. S. (2025) · Clinical Endoscopy · doi:10.5946/ce.2024.270 · Cited by 39
“2 In this review, we discuss clinical applications, advanced therapeutic strategies, and emerging research on FMT.”
InfluentialBascuñana, R. Á. P., Veses, V., & Sheth, C. C. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13486 · Cited by 42
Microbiota-targeted therapies in inflammation resolution
Strati, F., Lattanzi, G., Amoroso, C., & Facciotti, F. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101599 · Cited by 33
Wang, Y., Hunt, A., Danziger, L. H., & Drwiega, E. N. (2024) · Antibiotics · doi:10.3390/antibiotics13050436 · Cited by 32
“PUNCH-CD was a single-arm, open-label trial assessing AEs within 6 months of Rebyota administration as the primary outcome [84].”
BackgroundMethodInfluentialDuPont, H. L., Dupont, A. W., & Tillotson, G. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241253089 · Cited by 31
Donor Considerations in Fecal Microbiota Transplantation
Barnes, D. M., & Park, K. T. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0548-y · Cited by 32
Zhang, Y., Fleur, A. S., & Feng, H. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2052698 · Cited by 30
Infecciosas, I. D. I. S. G. M. S. D. M. C. Y. E., Bouza, E., Aguado, J. M., Alcalá, L., Almirante, B., Alonso‐Fernández, P., Borges-Sa, M., Cobo, J., Guardiola, J., Horcajada, J. P., et al. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/2065.2020 · Cited by 33
Garey, K. W., Dubberke, E. R., Guo, A. X., Harvey, A., Yang, M., García-Horton, V., Fillbrunn, M. K., Wang, H., Tillotson, G., Bancke, L. L., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad383 · Cited by 25
Self-citationMonday, L., Tillotson, G., & Chopra, T. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s419243 · Cited by 25
Therapies on the horizon forClostridium difficileinfections
McFarland, L. V. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1161025 · Cited by 29
“[82] Most (87%) did not report subsequent CDI recurrence.”
BackgroundCataldo, M. A., Granata, G., & Petrosillo, N. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1387535 · Cited by 28
“method have been released, respectively, a phase II trial on a microbiota suspension prepared from donated human stool [98] and a phase II trial on Firmicutes spores fractionated from 460 healthy donors stool specimens and then treated with ethanol to reduce the risk of transmissible infectious agent contamination [99…”
MethodPolymeric Films for the Encapsulation, Storage, and Tunable Release of Therapeutic Microbes
Qiu, K., Young, I. C., Woodburn, B. M. D., Huang, Y., & Anselmo, A. C. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901643 · Cited by 26
UEG Week 2016 Poster Presentations
Dargienė, G., Kupčinskas, J., Jonaitis, L. V., Urbonas, V., Aužbikienė, R., Frandsen, T. H., Kučinskienė, R., Kaduševičius, E., Kupčinskas, L., & Andersen, L. P. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616663689 · Cited by 27
Ray, A., & Jones, C. R. (2016) · Future Microbiology · doi:10.2217/fmb.16.10 · Cited by 23
Self-citationCurrent and future trends in clostridioides (clostridium) difficile infection management
Khanna, S., & Gerding, D. N. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.04.010 · Cited by 27
Greffe de microbiote fécal et infections: Mise au point, perspectives
Lagier, J., & Raoult, D. (2016) · médecine/sciences · doi:10.1051/medsci/20163211015 · Cited by 24
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection
Fehér, C., Soriano, À., & Mensa, J. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0140-z · Cited by 23
“) that demonstrated its efficacy in a multicenter open-label phase II study [218].”
BackgroundAldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
Cryopreservation of the human gut microbiota: Current state and perspectives
Smirnova, D. V., Заломова, Л. В., Zagaynova, A. V., Makarov, V. V., Mezhevikina, L. M., Fesenko, E. E., & Yudin, S. M. (2019) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2019.06.001 · Cited by 20
Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna, S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13290 · Cited by 23
Emerging drugs for the treatment of clostridium difficile
Cammarota, G., Gallo, A., Ianiro, G., & Montalto, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591371 · Cited by 20
Blount, K., Papazyan, R., Ferdyan, N., Srinivasan, K., Gonzalez, C., Shannon, W. D., & Fuchs, B. C. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae418 · Cited by 23
“These changes brought participants’ microbiomes closer to reported healthy compositions [29–33], and their microbiota converged toward the RBL compositions, which are reasonably representative of a healthier range since RBL is manufactured from stool from rigorously screened healthy donors [12, 34].”
Alhifany, A. A., Almutairi, A. R., Almangour, T. A., Shahbar, A. N., Abraham, I. L., Alessa, M. Y., Alnezary, F. S., & Cheema, E. U. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031145 · Cited by 17
Seida, I., Shawaf, M. A., & Mahroum, N. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103541 · Cited by 20
Yadav, D., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211009694 · Cited by 18
Orenstein, R. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00714-9 · Cited by 18
Self-citationTariq, R., Pardi, D. S., & Khanna, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231174293 · Cited by 17
Self-citationWang, J., Li, X., Wu, X., Wang, Z., Wu, X., Jin, G., Wang, D., & Yan, T. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s308308 · Cited by 18
Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention
Lavoie, T., Appaneal, H. J., & LaPlante, K. L. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad639 · Cited by 17
Metadata
- Authors
- Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S.
- Affiliations
- Mayo Clinic in Arizona (US)
- Washington University in St. Louis (US)
- Ochsner Medical Center (US)
- University of Chicago (US)
- Mayo Clinic (US)
- Henry Ford Health (US)
- Corresponding author
- Orenstein, Robert
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-12
- Volume
- 62
- Issue
- 5
- Pages
- 596-602
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2174455357
- Cited by
- 197
- References
- 30
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 34 · 2023: 24 · 2022: 19 · 2021: 15 · 2020: 16 · 2019: 17 · 2018: 17 · 2017: 14 · 2016: 20 · 2015: 1
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- recurrent Clostridium difficile infection, RBX2660, fecal microbiota transplantation, enema administration, drug safety, adverse events
- MeSH terms
- Fecal Microbiota Transplantation, Adult, Aged, Aged, 80 and over, Diarrhea, Enema, Enterocolitis, Pseudomembranous, Female, Humans, Male, Middle Aged, Prospective Studies, Recurrence, Clostridioides difficile, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.